NCT02173249View on ClinicalTrials.gov

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

AC 170 0.24%

1 drop in each eye 2 times daily for 1 week

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT02173249 - A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24% | Biotech Hunter | Biotech Hunter